Titrating steroids on exhaled nitric oxide in children with asthma: a randomized controlled trial.
BACKGROUND
Corticosteroids are the antiinflammatory treatment of choice in asthma. Treatment guidelines are mainly symptom-driven but symptoms are not closely related to airway inflammation. The fraction of nitric oxide in exhaled air (FENO) is a marker of airway inflammation in asthma.


OBJECTIVE
We evaluated whether titrating steroids on FENO improved asthma management in children.


METHODS
Eighty-five children with atopic asthma, using inhaled steroids, were allocated to a FENO group (n=39) in which treatment decisions were made on both FENO and symptoms, or to a symptom group (n=46) treated on symptoms only. Children were seen every 3 months over a 1-year period.


METHODS
Symptoms were scored during 2 weeks before visits and 4 weeks before the final visit. FeNO was measured at all visits, and airway hyperresponsiveness and FEV1 were measured at the start and end of the study. Primary endpoint was cumulative steroid dose.


RESULTS
Changes in steroid dose from baseline did not differ between groups. In the FENO group, hyperresponsiveness improved more than in the symptom group (2.5 vs. 1.1 doubling dose, p=0.04). FEV1 in the FENO group improved, and the change in FEV1 was not significantly different between groups. The FENO group had 8 severe exacerbations versus 18 in the symptom group. The change in symptom scores did not differ between groups. FENO increased in the symptom group; the change in FENO from baseline differed between groups (p=0.02).


CONCLUSIONS
In children with asthma, 1 year of steroid titration on FENO did not result in higher steroid doses and did improve airway hyperresponsiveness and inflammation.
Pijnenburg
Mariëlle W
MW
Department of Pediatrics, Erasmus University Medical Center/Sophia Children's Hospital, P.O. Box 2060, 3000 CB Rotterdam, The Netherlands. m.pijnenburg@erasmusmc.nl
Bakker
E Marije
EM
Hop
Wim C
WC
De Jongste
Johan C
JC
D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001944:Breath Tests; D016535:Bronchial Hyperreactivity; D019819:Budesonide / Q000008:administration & dosage*; D002648:Child; D005260:Female; D005541:Forced Expiratory Volume; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D009569:Nitric Oxide / Q000032:analysis*; D011241:Prednisone / Q000008:administration & dosage*
D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D009569:Nitric Oxide; D019819:Budesonide; D011241:Prednisone